BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- MEACOR Inc. is pleased to announce the successful closing of its $15 million Series A funding round. This substantial investment supports MEACOR's mission to offer a novel transcatheter approach for the treatment of mitral and tricuspid valve regurgitation. "This is a pivotal moment for MEACOR," said Toufic Azar, CEO and co-founder. "This funding round underscores the potential of our technology to enhance valvular heart repair. With this capital, we can strategically grow our team, to rapidly achieve critical milestones while ...